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Case Report
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Malignant transformation of urachal adenoma is exceedingly rare, with intestinal met-
aplasia as the most common contributing mechanism. It is recommended that a urachal 
adenoma be regarded as a pre-malignant condition and be subject to endoscopic 
surveillance. A local en block excision of the tumor mass with urachalectomy and um-
bilectomy results in possible long-term survival. The median survival after plati-
num-based chemotherapy is limited for patients with extravesical disease. Here we re-
port a case of synchronous urothelial carcinoma of the bladder and urachal adenoma 
that transformed into adenocarcinoma.
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Malignant transformation of a urachal adenoma into an ad-
enocarcinoma is exceedingly rare. Here we report a case of 
synchronous urothelial carcinoma of the bladder and ura-
chal adenoma with subsequent malignant transformation.
CASE REPORT
An 86-year-old female was diagnosed with superficial, 
low-grade, non-muscle-invasive urothelial carcinoma of 
the bladder in 1996. She had past medical histories of mul-
tiple sclerosis, thoracic aortic aneurysm, and supra-
ventricular tachycardia. After an initial transurethral re-
section (TUR), she remained asymptomatic and had no tu-
mor recurrence until October 2009. A single urothelial car-
cinoma situated near the left ureteric orifice was noted dur-
ing a routine flexible cystoscopy. An incidental 2.5-cm mu-
cus-secreting diverticulum at the dome of the bladder was 
also noted during the same procedure. A cold cup biopsy of 
the diverticulum wall was planned to occur simultaneously 
with a TUR of the bladder tumor. The TUR of the bladder 
tumor was performed and the histology confirmed a 
low-grade, non-muscle-invasive urothelial carcinoma. The 
bladder diverticulum was again visualized at the dome of 
the bladder during the procedure. Cold cup biopsies of the 
wall of the diverticulum revealed evidence of tubulovillous 
adenoma, possibly of urachal origin. Clinically, the patient 
had no palpable suprapubic mass and a triple-phase com-
puted tomography (CT) scan of the abdomen was normal. 
Since then, the patient had regular surveillance cystoscopy 
in accordance with the guidelines on TaT1 (non-muscle-in-
vasive) bladder cancer by the European Association of 
Urology. In 2011, the patient was again noted to have mi-
croscopic hematuria. She had no palpable mass on 
examination. The bladder diverticulum containing the 
urachal adenoma was again visualized.
An endoscopic resection of the urachal adenoma was per-
formed and macroscopic clearance of the tumor was 
achieved. The histology of the specimen revealed a moder-
ately differentiated adenocarcinoma, enteric subtype, 
with evidence of lamina propria infiltration (Figs. 1, 2). A 
staging CT scan showed a localized urachal lesion without 
extravesical extension. The umbilicus and the lymph nodes 
were unremarkable on the CT scan (Fig. 3). 
A diagnosis of urachal adenocarcinoma was made. After 
careful consideration, taking into account the patient’s 
age, co-morbidities, and the lack of radiological evidence of 
extravesical disease, a partial cystectomy and urachalec-
tomy was planned. The intravesical approach was used ini-
tially to identify the macroscopic extent of the tumor with 
a 1-cm margin marked out with a Barnes knife and with Korean J Urol 2012;53:438-440
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FIG. 2. High power field showing urachal adenocarcinoma, 
enteric subtypes (H&E, ×200). Some of these cells display 
cytoplasmic mucin and there is some luminal mucin.
FIG. 3. Computed tomography scan showing the urachal lesion 
located at the bladder dome (arrow). There was no lymphaden-
opathy or extra-vesical extension.
FIG. 1. Lower power field showing urachal adenocarcinoma, 
enteric subtypes (H&E, ×20).
the bladder full. Laparotomy was then performed with ex-
cision of the urachus from the base of the umbilicus down 
to and including the lesion in the bladder as previously 
outlined. Histology of the resected specimen showed no re-
sidual adenocarcinoma and clear resection margins.
DISCUSSION
A urachal lesion can be benign or malignant. Benign le-
sions are most commonly adenomas. Of the malignant le-
sions, over 80% are adenocarcinoma with enteric, muci-
nous, and signet ring subtypes, and the rest consist of sarco-
ma, urothelial carcinoma, and squamous cell carcinoma. 
About 69% of adenocarcinoma produces mucus and 15% 
does not [1]. Overall, the incidence of urachal carcinoma is 
0.07 to 2% [1]. A patient with urachal adenocarcinoma of-
ten presents with macroscopic hematuria. The mean age 
of presentation is 65 years [1]. Urachal tumors are situated 
at the junction of the urachus and the bladder. A CT scan 
of the abdomen may display tumor calcification and um-
bilical extension with extravesical disease. The location of 
the tumor at the bladder dome, the sharp demarcation be-
tween the tumor and the normal urothelium, the presence 
of urachal remnants, and the absence of cystitis glan-
dularis and cystitis cystic are diagnostic criteria for ura-
chal neoplasm [2].
Many staging systems have been proposed for urachal 
tumors. However, no system stands out given the paucity 
of urachal tumors. The recent reclassification of urachal tu-
mors by the Mayo clinic has simplified the previously 
known Sheldon system [1,3] The Mayo staging system di-
vides urachal tumors into four stages: stage I, tumor con-
fined to urachus and bladder; stage II, tumor extending be-
yond urachus and bladder; stage III, tumor infiltration of 
regional nodes; and stage IV, tumor infiltration of non-re-
gional nodes and distant sites. Most of the tertiary in-
stitutions adopt a multi-modal approach when treating pa-
tients with a urachal tumor. A local en bloc excision of the 
tumor mass with urachalectomy and umbilectomy results 
in possible long-term survival. The median survival after 
platinum-based chemotherapy is limited for patients with 
extra-vesical disease [4].
Intestinal metaplasia is the most common mechanism 
causing the transformation of a urachal adenoma into 
adenocarcinoma. Only 30 cases of villous adenoma have 
been found outside the large bowel, and only 4 cases of ad-
enocarcinoma arising within a villous adenoma have been 
reported [5-7]. The hypothesis was that a urachal tubulo-
villous adenoma shares similar oncogenes and tumor sup-
pressor protein such as p53 with colonic tubulovillous 
adenoma. The progression from colonic adenoma to ad-
enocarcinoma is genetically well characterized and thus 
may be applicable in urachal tumors. Urachal adenoma 
and adenocarcinoma may in fact co-exist in a solitary le-Korean J Urol 2012;53:438-440
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sion, representing a different spectrum of tumorigenesis. 
A cold cup biopsy of a sizable urachal lesion can hence be 
falsely reassuring. It is recommended that a urachal ad-
enoma be regarded as a premalignant condition and be sub-
ject to endoscopic surveillance. Synchronous low-grade, 
non-muscle-invasive urothelial carcinoma and urachal ad-
enoma is rare and there is no known genetic link between 
the two malignancies.
The optimal management of synchronous urothelial car-
cinoma and urachal adenoma is not known. The potential 
for malignant transformation of the urachal adenoma into 
adenocarcinoma proposes a unique clinical challenge. 
Regular endoscopic surveillance of the urachal adenoma 
should be mandated; however, a protocol is difficult to for-
mulate given the rarity of the urachal lesion. One needs to 
weigh the rarity of the disease against its malignant poten-
tial when making a clinical decision. 
A partial cystectomy with en bloc resection of urachal ad-
enocarcinoma seems to be the widely accepted surgical ap-
proach for localized urachal adenocarcinoma. A study by 
Memorial Sloan Kettering Cancer Center showed a surviv-
al rate of 93% at 5 years with partial cystectomy [8]. A study 
by the Mayo clinic showed a median survival of 10.8 years 
for stage I/II disease and only 1.3 years for stage IV disease 
[4]. This compares similarly with the 5-year survival data 
for T1 high-grade urothelial carcinoma after radical cys-
tectomy and favorably with the 5-year survival data for 
muscle-invasive urothelial carcinoma [9]. We recommend 
the use of the European Association of Urology urothelial 
carcinoma endoscopic surveillance protocol for a solidary 
urachal adenoma and also in the setting of a synchronous 
low-grade, superficial urothelial carcinoma with a urachal 
adenoma. 
In conclusion, synchronous bladder urothelial carcino-
ma and urachal adenoma is rare. Clinicians need to be 
aware of the premalignant potential of urachal adenoma, 
and an endoscopic surveillance program should be 
instigated. The late adenoma to adenocarcinoma trans-
formation should be managed with partial cystectomy and 
en bloc resection of the urachus and umbilicus in well-se-
lected patients. 
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